Begin clinical trial of KB407 for cystic fibrosis
Not delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 1 Mar 2021
- Due
- 30 Jun 2021
- Checked
- 26 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Clinical trial initiation is anticipated in 1H21”
What we found
Evidence strength A What the grades mean
Filings after the 1H21 deadline say trial initiation was anticipated in 4Q21, later moved to 1H22, with no start by the deadline shown.
-
A Krystal Biotech, Inc. 10-Q filed 2021-11-08
“trial initiation is anticipated in 4Q21” ✓ confirmed on the page
-
A Krystal Biotech, Inc. 10-K filed 2022-02-28
“We plan to initiate the Phase 1 clinical trial in Australia in the first half of 2022.” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Begin
- Deliverable
- Clinical trial initiation of KB407 for cystic fibrosis
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Krystal Biotech, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-KRYS-024833 · Corrections policy